Health
Why Might Cassava Succeed With Its Alzheimer’s Drug, When So Many Have Failed? – The Motley Fool
Alzheimer’s research has been hampered by apparently mistaken ideas about what causes the disease. Cassava has a new theory about…
Cassava Sciences(NASDAQ:SAVA) is like any other unprofitable biotech — it has a drug in clinical trials, and its investors are hoping the drug works so they can make a lot of money. What makes Cassava really interesting is that it’s zigging where Big Pharma…
Continue Reading
-
Business21 hours ago2 must-have ASX shares to buy for dividend income investors
-
Noosa News24 hours agoSA landscape boards crack down on illegal dams in Mount Lofty Ranges
-
General23 hours agoMontana’s house was gutted by an accidental fire. Then her landlord accused her of starting it
-
Business23 hours agoThe smartest ASX dividend stocks to buy with $5,000 right now